WILMINGTON, DE — Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), combined with pertuzumab, delivered a highly ...

A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is designed to help adults with certain types of advanced cancer that cannot be ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate (ADC) bearing a deruxtecan (TOP1 inhibitor) warhead, was developed by Japanese pharmaceutical company Daichi Sankyo. A ...

The Jeep Wrangler has offered a partially electric model for several years now with the plug-in-hybrid 4xe.However, it will soon be joined by an all-electric alternative. Enter the Jeep Recon.Like ...

Enhertu is an antibody-drug conjugate. Here’s how it treats HER2-positive and HER2-low breast cancer.

Everything we know about the Recon, a fully electric off-road SUV that blazes a trail for an eventual electric Wrangler 4x4. Everything we know about Jeep’s new electric off-road SUV. MotorTrend ...

Enhertu has been called a breakthrough in breast cancer treatment. While it doesn’t cure HER2 breast cancer, research shows that it provides patients with more time. According to the National Library ...

AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of ...

A report from MoparInsiders claims Stellantis is accelerating plans for the Jeep Recon EV. The electric off-roader will allegedly enter production in Q1 2025.

Enhertu approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer. News release. AstraZeneca and Daiichi Sankyo. Accessed August 8, 2022.